A new plant manufacturing toluene diisocyanate (TDI) has provided a unique opportunity to investigate the effects of TDI vapor inhalation on respiratory health in a group of exposed workers who have been studied prior to the start of plant operation. In order to establish dose-response relationships and determine host factors, complete biologic monitoring, including pulmonary function and immunologic studies, has been performed concurrently with a comprehensive environmental monitoring program including continuous sampling for atmospheric concentrations of TDI. Study groups include workers with regular exposure to TDI in production jobs (83), workers with intermittent contact with this vapor, usually in maintenance (28), and a control group of workers employed outside the TDI area (55). This population is being followed for a period of 5 yr.
A new plant manufacturing toluene diisocyanate (TDI) has provided a unique opportunity to investigate the effects of TDI vapor inhalation on respiratory health in a group of exposed workers who have been studied prior to the start of plant operation. In order to establish dose-response relationships and determine host factors, complete biologic monitoring, including pulmonary function and immunologic studies, has been performed concurrently with a comprehensive environmental monitoring program including continuous sampling for atmospheric concentrations of TDI. Study groups include workers with regular exposure to TDI in production jobs (83), workers with intermittent contact with this vapor, usually in maintenance (28) , and a control group of workers employed outside the TDI area (55). This population is being followed for a period of 5 yr.
The plant began operations in August 1973 with start-up procedures completed by the end of October. TDI spills occurred for numerous reasons, usually attributed to pump failure and resultant line blockage. Significant exposures also occurred in the drumming operation. The influence of these malfunctions is noted in the continuous monitoring data on atmospheric TDI concentrations which continue to reveal frequent excursions above the threshold limit value (TLV) of 0.02 ppm ceiling. These data are presented in relation to time and plant location.
Although the first full year follow-up following initial exposure was not complete, certain preliminary clinical observations were made. A number of workers had episodes of acute respiratory symptoms related to single exposure to an irritant gas at work, usually either TDI or phosgene. It appears that two or three workers in the study population have become "clinically sensitized" to TDI and have been removed from regular TDI exposure. To date, the total number of workers who report the presence of recurring respiratory symptoms has not increased in comparison with the pre-exposure survey.
Pulmonary function data after one full year of TDI exposure are not yet available. Pre-and post-shift ventilatory function studies do not indicate significant differences between the exposed and control groups. Selected individuals had carefully controlled inhalation challenge tests to monitored concentrations of TDI vapor under laboratory conditions. In workers suspected of having become "sensitized", immediate and/or late air flow obstruction was demonstrated and could be related to dose of inhaled TDI. Although it has been recognized for over 20 turing or polyurethane foam operations, comyears that an asthmatic or bronchitic response prehensive investigations designed to provide may be detected in workers exposed to toluene correlation of clinical, physiologic, immunologic diisocyanate (TDI) vapor, either in manufac-and environmental data, have not thus far been attempted. (55) . The total study population of 166 was studied prior to start-up of TDI production and has been followed by clinical, pulmonary physiologic, and immunologic methods since the beginning of exposure.
Methods of Biologic Monitoring
Clinical An initial questionnaire was administered by a trained interviewer using the National Heart and Lung Institute modification of the British MRC questionnaire with the addition of several questions adopted for this study. A follow-up questionnaire was designed by the investigators to detect change in respiratory health with the detection of any new or more prominent respiratory symptoms which may be associated with exposure at work.
Immunologic
In April-May 1973, prior to commencement of TDI production, a visit was made to the plant to collect pre-exposure blood samples for eosinophil counts, immunoglobulin levels, and antibody assays, and to perform skin tests with common inhalant allergens and TDI-human serum albumin conjugates. A second visit was made in November-December, 1973 , when blood samples were again collected following commencement of TDI production.
Serum was separated from the blood samples at the plant, frozen, and stored at -70°C until used to quantitate immunoglobulin levels (IgG, IgA, IgM, IgD, IgE), perform guinea pig PCA and monkey P-K tests, and detect anti-TDI antibodies by the radioimmunoassay and passive hemagglutination techniques.
Conjugation of TDI to Serum Albumin: TDI was conjugated to human and bovine serum albumin. In an ice bath, 100 ml of a 1%o solution of the protein in 0.85% sodium chloride was adjusted to pH 8.5 with 1N NaOH. To this, 100 ml of 20 mg-%0 TDI in dioxane was added slowly over a 3-hr period, maintaining pH at 8.5 with 1N NaOH. 
Immunoglobulin Quantitation: Immunoglobulins G, A, M, and D were quantitated by the single radial diffusion technique (1). IgE was quantitated by the radioimmunoassay technique described previously (2) .
Anti-TDI Antibody Quantitation: Circulating anti-TDI antibodies were assayed for by two methods: radioimmunoassay by use of Sephadex G-25 superfine to which HSA-TDI antigen had been conjugated (2) excursions have occurred during the start-up, and have continued since the plant has been on line. The proportion of sampling periods with excessive concentrations has diminished overall since start-up was completed ( (Fig. 5) . Considerable effort by the plant personnel is continuing in order that TDI exposures can be minimized so that average concentrations will be reduced.
Biologic Response
Clinical, physiologic, and immunologic data are markedly limited, since at the time of this report, the first full year of exposure has not yet elapsed. As of this time, a number of workers have presented with acute respiratory symptoms, generally short-lived, resulting from a single exposure to an irritant gas or vapor, usually phosgene or TDI. Most workers can accurately report which exposure had occurred, and often there is an associated recognizable malfunction as the source of his exposure. Ten to twelve workers appear to have become "clinically sensitive" to TDI vapor with such recurrent respiratory symptoms as cough, shortness of breath, chest tightness, and wheezing occurring after what seems to them to be minimal exposure to this vapor. These symptoms may have followed a heavy exposure to TDI initially but in some instances such a single episode did not seem to occur. These individuals have been removed from the TDI area to another part of the chemical manufacturing complex Inhalation challenge tests to TDI produced a variety of patterns in those clinically sensitized workers studied to date. A reduction in ventilatory function may occur both immediately following exposure and again several hours later, this late response being quite variable in degree and time required for recovery, the latter at times being longer than 24 hr. The characteristic dual response is shown in Figure  6 . Another worker exhibited only a slight immediate reduction in ventilatory function and also demonstrated the greater sensitivity of the forced expiratory flow, 25-75%, in contrast to the more commonly measured forced expiratory volume, 1 sec (Fig. 7) . 
